Better than the second-line standard treatment CAR-T therapy to reach the phase 3 clinical primary endpoint

Bristol-Myers Squibb Company (BMS) today announced that its CD19-targeted CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) has reached the primary and key secondary endpoints in a phase 3 clinical trial, significantly improving recurrence compared with standard treatment /Event-free survival, complete remission rate and progression-free survival of patients with refractory large B-cell lymphoma (LBCL)

Breyanzi is an autologous CAR-T cell therapy targeting CD19 antigen.

A randomized double-blind pivotal phase 3 clinical trial called TRANSFORM was launched in adult patients with large B-cell lymphoma who relapsed within 12 months of receiving initial treatment

Note: The original text has been deleted

Reference materials:

[1] Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma.